Amantadine is a prescription medication used for Parkinson's disease and related movement disorders, and it also has a long history of use against influenza A. Patients and employers sometimes ask whether it will show up on a workplace or clinical drug test, or whether it could trigger an unexpected positive result. This article explains how standard drug test panels are built, what amantadine actually is from a chemistry standpoint, what the published evidence says about cross reactivity, and how a medical review officer (MRO) handles a prescribed medication during the testing process.
What amantadine is and what it is prescribed for
Amantadine is an adamantane derivative. According to its current prescribing information on DailyMed, amantadine is indicated for Parkinson's disease and Parkinsonian syndrome, for drug induced extrapyramidal reactions, and it has also been used for influenza A. MedlinePlus describes amantadine as a medication that helps control tremor, stiffness, and other movement symptoms by affecting dopamine activity in the brain. It is taken by prescription only and is dispensed under a specific National Drug Code, which is the detail a laboratory or an MRO can verify against a pharmacy record.
Amantadine is not a controlled substance under the Controlled Substances Act. It carries no abuse potential classification and is not scheduled, which is one reason it is not built into standard drug of abuse panels in the first place.
How a standard drug test panel is built
Workplace and clinical drug tests, including the cups, dip cards, and oral fluid devices American Screening Corporation manufactures, are built around specific drug classes. The federal workplace testing rule at 49 CFR 40.85 lists the classes a laboratory must test for in a federally regulated program: marijuana metabolites, cocaine metabolites, opioids, phencyclidine, and amphetamines (including methamphetamine, MDMA, and related compounds). A standard five panel or ten panel device is built to react to those specific drug classes and their listed metabolites, not to every medication a person might be taking.
Amantadine is not chemically related to any of those target classes. It is not a phenethylamine like amphetamine or methamphetamine, it is not an opioid, and it is not a cannabinoid. Because the immunoassay strips used for initial screening are designed to bind to molecules that resemble the target drug closely enough to trigger a reaction, a medication with a structurally distinct ring system such as amantadine would not be expected to react with most panel antibodies as a routine matter.
| Attribute | Amantadine | Amphetamine or methamphetamine (panel target) |
|---|---|---|
| Drug class | Adamantane derivative, antiviral and antiparkinsonian agent | Phenethylamine stimulant |
| Controlled substance status | Not controlled or scheduled | Schedule II |
| Included on a standard 5 panel or 10 panel | No, not a built in target | Yes, a standard target class |
| Typical screening method | Not applicable, no dedicated strip | Immunoassay cup, dip card, or oral fluid device |
| Confirmation method when a screen is positive | Not applicable unless separately tested for | GC/MS or LC/MS/MS at a certified laboratory |
| Published cross reactivity evidence | Limited, see below | Not applicable, it is the intended target |
Screening immunoassay versus lab confirmation
It helps to separate the two stages of testing. The initial screen, whether it is a urine cup, a dip card, or an oral fluid device, is an immunoassay. It gives a rapid presumptive result by detecting whether a sample reacts strongly enough with an antibody tuned to a target drug class. An immunoassay can occasionally react to a structurally similar compound that is not the actual target drug, which is the basis of most cross reactivity and false positive discussions.
A presumptive positive screen is not a final result. Samples that screen positive are referred for confirmation testing using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS). These methods identify the exact molecule present rather than reacting to a family of similar compounds, so they do not share the cross reactivity limitations of an immunoassay. Confirmation testing is the step that distinguishes an actual amphetamine from a medication that may have triggered a nonspecific screening reaction.
What the published evidence says about amantadine and cross reactivity
There is limited published evidence connecting amantadine to a false positive amphetamine immunoassay result. A case report indexed on PubMed describes a false positive urine screen for amphetamine in a patient who had taken amantadine together with another prescription medication, desipramine. That report is a single clinical case rather than a controlled laboratory study of amantadine cross reactivity on its own, and it involved a combination of two medications rather than amantadine in isolation. Outside that case report, there is no broader published laboratory validation data showing that amantadine by itself reliably triggers amphetamine immunoassay screens at the cutoffs used in current workplace or clinical panels.
Because the evidence is limited to one older case description rather than a body of validation studies, the honest summary is that cross reactivity between amantadine and amphetamine immunoassays is possible but not well established, and it has not been shown to be a routine or predictable occurrence. Anyone who takes amantadine and receives an unexpected positive screen should rely on the confirmation and MRO review process described below rather than assuming the medication is or is not the cause.
What should happen if a prescribed medication produces an unexpected result
In a regulated workplace testing program, a nonnegative screening result does not go straight to an employer. It is reviewed by a medical review officer, a licensed physician trained specifically in this review process under 49 CFR Part 40 Subpart G. The MRO contacts the individual, reviews the laboratory confirmation data, and asks about current prescriptions and over the counter medications. A valid prescription for a legitimately prescribed medication, documented and verified with the prescribing provider or pharmacy, is part of what the MRO considers before a final result is reported. This is also why keeping a current prescription label or pharmacy printout available for a scheduled test is useful, since it gives the MRO something concrete to verify quickly.
This process exists specifically so that a medication history, not a guess about chemistry, decides how an unexpected screening result is resolved. Neither a patient nor an employer should try to interpret a presumptive screen on their own, and this article is not a substitute for that review.
What this means for employers and testing programs
For employers running a drug free workplace program, the practical takeaway is that amantadine is not a medication that needs a special note added to a testing policy. It is not on the standard panel, it is not a controlled substance, and the single case report describing a false positive involved a medication combination rather than amantadine alone. Programs that already follow standard SAMHSA certified laboratory practices and route nonnegative results through an MRO, as discussed in our related post on how certain Parkinson medications can read as methamphetamine on a screen, already have the right process in place to catch and resolve a rare cross reactivity question for any medication, amantadine included. Our post on whether modafinil shows up on an amphetamine screen covers a similar structural cross reactivity question for a different medication class.
Employers and clinics that want a closer look at the devices used for initial screening, including the amphetamine and methamphetamine panel strips referenced in this article, can review options through our drug test cup collection.
Frequently asked questions
Does amantadine show up as a positive result on a standard drug test?
No. Amantadine is not a controlled substance and is not built into standard amphetamine, opioid, cannabinoid, cocaine, or PCP immunoassay panels, so a routine screen is not designed to detect it or react to it as a matter of course.
Can amantadine cause a false positive for amphetamines?
There is limited published evidence of this. A single case report describes a false positive amphetamine screen in a patient taking amantadine together with another medication, desipramine. Outside that case, there is no broader published data showing amantadine alone reliably causes this reaction.
Is amantadine a controlled substance?
No. Amantadine is not scheduled under the Controlled Substances Act and carries no federal abuse potential classification.
What should someone taking amantadine do before a scheduled drug test?
Bring current prescription information. If a screening result comes back nonnegative for any reason, a medical review officer will ask about current medications, and documented prescriptions are part of that review.
How is an unexpected positive screening result confirmed?
Laboratories confirm any presumptive positive immunoassay result with GC/MS or LC/MS/MS testing, which identifies the specific molecule present rather than reacting to a family of similar compounds.
Who decides whether a prescribed medication explains a test result?
A medical review officer, a licensed physician trained under 49 CFR Part 40 Subpart G, reviews laboratory data and medication history before a final result is reported in a regulated testing program.
This article is general information about drug test science and testing procedure, not legal or medical advice. Anyone with questions about a specific medication or test result should talk with a qualified physician, pharmacist, or medical review officer.
